fda semaglutide obesity Kids approved for weight loss drugs! US FDA approves weight loss

During a period of high demand and limited supply, the FDA allowed pharmacies to compound GLP-1s to help patients maintain access while manufacturers scaled up production

Remove the needle from the pen: After injecting, dispose of the needle in a safe, sharp object container

Comparative safety assessment demonstrated a statistically significant reduction in adverse reaction incidence with combination therapy (GLP-1 receptor agonists plus metformin) compared to monotherapy

What Retatrutide Is and Why It Attracted So Much Attention Retatrutide is a triple agonist, meaning it simultaneously activates three distinct hormonal receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR)